Annonce • May 07
University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry ZIVO Bioscience, Inc. announced positive results from its second collaborative study with the University of Delaware evaluating the efficacy of several formulations of ZIVO's proprietary active ingredients in mitigating the spread of Low Pathogenicity Avian Influenza (LPAI) virus among poultry. Building upon the outcomes of the initial study, this second study aimed to assess and compare the performance of three different ZIVO formulations in both directly challenged and contact-exposed birds. The study affirmed earlier observations that ZIVO's active ingredients may positively influence LPAI transmission dynamics, while identifying the optimal formulation for further testing. In the first arm of the study, which involved birds receiving a direct challenge with LPAI, modest positive trends were observed in viral shedding reduction among ZIVO-treated groups compared with untreated controls. While these differences did not reach statistical significance, the findings suggest potential for ZIVO's formulations to lessen disease severity. Notably, the formulation consisting of a blend of four distinct algal-derived materials demonstrated a slower and less efficient spread of the virus. One bird treated with this combination showed no signs of infection post-exposure, indicating potential protective effects. These findings resulting from rigorous testing at the University of Delaware reinforce commitment to developing sustainable, non-antibiotic solutions for the poultry industry. The insights gained from this study show encouraging trends and identifying a superior formulation will be instrumental in guiding future research and product optimization efforts. Given the potential impact ZIVO's product can have on mitigating Avian influenza, a widespread issue in the nation's large poultry industry, the company submitted a funding request to the State of Michigan for $5.5 million to further research. Additionally, the company are applying for a portion of the previously announced $100 million Avian Influenza Poultry Innovation Grand Challenge from the USDA. Annonce • Apr 28
ZIVO Bioscience, Inc., Annual General Meeting, Jun 09, 2025 ZIVO Bioscience, Inc., Annual General Meeting, Jun 09, 2025. Location: 2125 butterfield road, suite 100, mi 48084, troy, United States Annonce • Dec 21
ZIVO Bioscience, Inc. Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza Zivo Bioscience, Inc. reported favorable results from a study conducted in collaboration with the University of Delaware that evaluated the potential of ZIVO's proprietary active ingredients to reduce the transmission of Low Pathogenicity Avian Influenza (LPAI) virus among poultry. Key findings of statistical significance from the study include: A reduction in viral titers (viral shedding) in infected birds receiving ZIVO's products compared with untreated infected controls. A delay in transmission of LPAI when healthy birds were exposed to infected birds, suggesting a slower and less aggressive spread of disease. The two-part controlled study evaluated the efficacy of ZIVO's proprietary Active ingredients, previously shown to be efficacious for mitigating the effects of coccidiosis in broiler chickens, against LPAI. In the second part, healthy chickens were housed with infected birds, replicating a real-world, high-risk environment for disease transmission. Compared to an untreated control group, birds that received ZIVO's proprietary active ingredient that were housed with infected birds experienced a statistically significant delay in viral detection. This observed delay suggests that ZIVO's products limit viral replication within a host. These favorable results indicate that ZIVO's proprietary active Ingredients represent potential preventative measures for reducing the spread of LPAIV in commercial poultry operations and enhancing overall flock health. Multiple products were explored to identify the most effective strategies against LPAI. While some products were better at lowering the viral titer, others were more effective at slowing the spread, suggesting that an optimal product configuration could provide more comprehensive protection. The study's positive outcomes justify further research and product development, supporting the potential of ZIVO' pipeline to address both LPAIV infections as well as a broad spectrum of other viral challenges faced by the poultry industry. "The University of Delaware's findings provide compelling evidence that its feed ingredients could be valuable tools in mitigating the risk of avian influenza outbreaks without the limitations associated with vaccines. Reducing disease transmission can positively impact both animal welfare and the operations of producers. These study results represent a significant milestone in efforts to deliver science-driven, sustainable solutions to address serious challenges facing the global poultry industry". Annonce • Aug 23
ZIVO Bioscience, Inc. Reports Favorable Results from 42-Day Confirmatory Study of its Coccidiosis Treatment in Broiler Chickens ZIVO Bioscience, Inc. reported favorable results from its latest 42-day study with its product targeting coccidiosis in broiler chickens. The study, which was conducted in collaboration with a major global animal health company and replicated real-world poultry production environments, further validates the efficacy of ZIVO’s non-antibiotic, immune-modulating product designed for the treatment of coccidiosis. Funded by the major animal health company, the study focused on the overall health and productivity of birds challenged with the coccidiosis-causing parasite, Eimeria, while comparing administration of ZIVO’s product alone or in combination with either an ionophore-based treatment or a coccidiosis vaccine versus birds treated with the ionophore or vaccination alone. Uninfected/untreated healthy birds and infected/untreated birds served as negative and positive disease controls, respectively. In this study, broiler chickens infected with coccidiosis and treated with ZIVO’s product in combination with an anticoccidial ionophore or vaccination exhibited statistically significant improvements in both growth performance (as measured by feed conversion ratio, FCR) and clinical signs of disease (as measured by intestinal lesion scores), compared with chickens that received only the ionophore or vaccine. With respect to FCR over the 42-day grow-out period, groups treated with ZIVO’s product in combination with either the ionophore or vaccination performed on par with the healthy, uninfected control group. Annonce • Apr 28
ZIVO Bioscience, Inc., Annual General Meeting, Jun 11, 2024 ZIVO Bioscience, Inc., Annual General Meeting, Jun 11, 2024, at 10:00 US Eastern Standard Time. Location: 3600 Centerpoint Parkway Pontiac United States Agenda: To consider and approve the appointment of independent registered public accounting firm for the fiscal year ending December 31, 2024; to consider and approve the compensation of executive officers; and to consider and approve any other matters. Annonce • Feb 08
ZIVO Bioscience, Inc. Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study Zivo Bioscience, Inc. announced additional findings from its 42-day coccidiosis challenge study that demonstrate the product’s positive impact on the cost of broiler production as an alternative to commonly-used antibiotics. ZIVO’s product candidate for use in poultry feed is designed to boost immune response, allowing birds to effectively combat coccidiosis and reduce the negative effects of the disease without the use of antibiotics. These new results, along with earlier findings, further demonstrate the benefits of ZIVO’s product across the broiler production value chain. ZIVO previously reported the effects of its product on the health of broiler chickens exposed to coccidiosis during the course of a 42-day grow out period, which is typical for the poultry industry. These health benefits included a statistically significant reduction in intestinal damage caused by the Eimeria parasite compared with untreated control birds. This improvement in intestinal health following parasite exposure was on par with the market-leading commercial ionophore. ZIVO now reports that this reduction in intestinal damage enables poultry farms to optimize feed utilization as measured by the Feed Conversion Ratio (FCR), which is the primary driver of profitability. Similar to the outcomes related to intestinal damage, ZIVO’s product resulted in a statistically significant improvement in FCR compared with untreated controls. Further, these results were not statistically different from the market-leading commercial ionophore. Annonce • Jan 23
Zivo Bioscience Reports Positive Efficacy Results from 42-Day Validation Study with Non-Antibiotic Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens Zivo Bioscience, Inc. announced positive efficacy results following its recent 42-day coccidiosis challenge study further demonstrating the effectiveness of its novel immune-modulating treatment for coccidiosis in broiler chickens. ZIVO’s product candidate for use in poultry feed is designed to boost immune response, allowing birds to effectively combat coccidiosis and reduce the negative effects of the disease without the use of antibiotics. With these and earlier test results, ZIVO will pursue a partnership with a global animal health company for commercializing its coccidiosis product. The study design was similar to that of a previously successful 28-day challenge study but was extended through 42 days to replicate real-world conditions of the broiler production industry. The results of the study in which the ZIVO treatment groups and a placebo control were blinded to the independent study contractor confirm previously reported positive effects of ZIVO’s non-antibiotic alternative for maintaining broiler health against coccidiosis. Notably, the study also showed that the performance of ZIVO’s product candidate was comparable to that of a market leading anticoccidial product. Annonce • Jan 18
ZIVO Bioscience, Inc. announced that it has received $0.531142 million in funding On January 16, 2024, ZIVO Bioscience, Inc. closed the transaction. Annonce • Nov 29
Nasdaq Determines to Delist the ZIVO Bioscience's Common Stock from the Nasdaq Capital Market On November 22, 2023, the ZIVO Bioscience, Inc. was notified by The Nasdaq Stock Market LLC (“Nasdaq”) that as a result of the Company’s previously disclosed noncompliance with Nasdaq Listing Rule 5550(b)(1), Nasdaq has determined to delist the Company’s common stock from the Nasdaq Capital Market and, accordingly, will suspend trading in the Company’s common stock effective at the open of business, on November 27, 2023. Nasdaq further indicated that it will file a Form 25 Notification of Delisting with the Securities and Exchange Commission (the “SEC”). The Company has applied to have its common stock quoted on the OTC Markets’ OTCQB® market tier, an electronic quotation service operated by OTC Markets Group Inc. for eligible securities traded over-the-counter. Pending approval, the Company expects that trading of the Company’s common stock will commence on the OTC Pink Sheets at the open of business on November 27, 2023. The transition to the quotation of the Company’s common stock on the OTC Markets will have no effect on the Company’s business or operations. New Risk • Oct 29
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$6.0m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-US$3.1m). Revenue is less than US$1m (US$4.1k revenue). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$7.7m net loss next year). Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (US$27.7m market cap). Annonce • Oct 27
ZIVO Bioscience Announces Reverse Stock Split to Regain Compliance with the Nasdaq Stock Market’s Continued Listing Requirements ZIVO Bioscience, Inc. announced that the Board of Directors of the Company approved a 1-for-6 reverse stock split (the “Reverse Stock Split”) of its shares of common stock, par value $0.001 (the “Common Stock”) effective at 5:00 p.m. ET on October 26, 2023 (the “Effective Time”). The Company’s Common Stock will begin trading on a split-adjusted basis on October 27, 2023 and will continue to trade on the Nasdaq Capital Market under the existing symbol “ZIVO.” The new CUSIP number for the Common Stock following the reverse split is US98978N3098. As a result of the Reverse Stock Split, every 6 shares of authorized Common Stock will be automatically combinedinto one share of Common Stock. The Reverse Stock Split will reduce the number of authorized shares of Common Stock from 150,000,000 shares to 25,000,000 shares and the ownership percentage of each stockholder will remain unchanged other than as a result of fractional shares. The Company will pay cash for fractional shares, determined by multiplying such fraction by the closing sales price of the Company’s Common Stock as reported on Nasdaq on the last trading day before the Reverse Stock Split becomes effective (on a split-adjusted basis). The Reverse Stock Split is part of the Company’s plan to regain compliance with the Nasdaq Stock Market’s continued listing requirements. New Risk • Oct 07
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.72m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$6.0m free cash flow). Negative equity (-US$3.1m). Revenue is less than US$1m (US$4.1k revenue). Market cap is less than US$10m (US$9.72m market cap). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$7.7m net loss next year). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (11% increase in shares outstanding). Annonce • Sep 20
Trial Results Confirm Efficacy of ZIVO Bioscience’s Non-Antibiotic Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens Zivo Bioscience, Inc. announced positive results from a month-long coccidiosis trial in broiler chickens that was conducted by an independent veterinary research provider. The study evaluating the Company’s novel immune-modulating biologic for treating coccidiosis in broiler chickens examined multiple product lots as well as multiple product test concentrations and produced statistically significant positive outcomes in the treated groups. Coccidiosis is a protozoal disease that causes diarrhea, weight loss, decreased performance, and increased mortality in poultry. This disease represents a significant economic challenge for the global poultry industry, as indicated by a 2020 study that estimated annual costs ranging from $10 billion to $17 billion (Re-calculating the Cost of Coccidiosis in Chickens; Blake, D., Knox, J., et al.). Products for treating coccidiosis are mostly antibiotic or ionophore-based, and no commercially significant new technology has been introduced in the past 60 years. The disease challenge used in this trial closely replicated conditions often seen in commercial broiler production facilities experiencing a coccidiosis outbreak, including commercially relevant incidence and severity of intestinal lesions, mortality, and other disease related measures. Birds treated with ZIVO’s product candidate demonstrated statistically significant improvements across all measures of broiler health examined. Diseased chickens treated with elevated doses of ZIVO's product candidate exhibited reductions in disease-related effects to a level seen in healthy birds. The results of this recent study of multiple product batches, including product used in the inconclusive study earlier this year, align with those of over 20 prior successful trials that closely replicated disease levels observed in commercial production settings. Thus, validating that ZIVO’s product candidate maintains stability over an extended period, with no decrease in its effectiveness. As a result, ZIVO remains confident that its novel product candidate for broiler chickens presents a disruptive solution to coccidiosis, one of the most significant challenges facing the global poultry industry. Annonce • Aug 10
Nasdaq Hearings Panel Grants Zivo Biosciences's Request to Provide an Extension Until November 20, 2023 to Regain Compliance with the Stockholders’ Equity Rule for Continued Listing on Nasdaq On August 4, 2023, Zivo Biosciences, Inc. (the ‘Company’) received a notification letter from The Nasdaq Stock Market LLC (‘Nasdaq’) notifying the Company that the Panel has granted the Company’s request to provide an extension until November 20, 2023 (the ‘Exception Period’), to regain compliance with the Stockholders’ Equity Rule for continued listing on Nasdaq. The Panel further noted that the Exception Period for continued listing is subject to a filing of a registration statement on Form S-1 by the Company with the U.S. Securities and Exchange Commission (the ‘SEC’) on or before October 5, 2023. The Panel concluded that the Exception Period is justified in this case in light of the Company’s efforts to resolve its current equity deficiency and the steps it has taken thus far to prepare for regaining compliance. The Panel further noted that it does not view the Company’s continued listing during the exception period to be an undue risk to the financial markets nor prospective investors (the ‘Panel’s Decision’). As previously disclosed on May 26, 2023 by the company, the Company received a notification letter from The Nasdaq Stock Market LLC (‘Nasdaq’) on May 23, 2023, notifying the Company that it was not in compliance with the stockholders’ equity requirement of $2,500,000, as set in Nasdaq Listing Rule 5550(b) (the ‘Stockholders’ Equity Rule’). On May 30, 2023, the Company requested a hearing with the Nasdaq Hearings Panel (‘Panel’), which was held on July 13, 2023. At the hearing, the Company presented its plan to regain compliance with the Stockholders’ Equity Rule. In addition, during the Exception Period, the Panel reserves the right to reconsider the terms of this exception based on any event, condition or circumstance that exists or develops that would, in the opinion of the Panel, make continued listing of the Company’s securities on Nasdaq inadvisable or unwarranted. Furthermore, until the end of the Exception Period, the Company is required to provide prompt notification to the Panel of any significant events that may affect the Company’s compliance with Nasdaq requirements. The Company intends to regain compliance with the Stockholders’ Equity Rule prior to the end of the Extension Period set in the Panel’s Decision. However, until Nasdaq has reached a final determination that the Company has regained compliance with the applicable Nasdaq requirements, there can be no assurances regarding the continued listing of the Company’s securities on Nasdaq. The delisting of the Company’s securities from Nasdaq would have a material adverse effect on the Company’s access to capital markets, and any limitation on market liquidity or reduction in the price of its common stock as a result of that delisting would adversely affect the Company’s ability to raise capital on terms acceptable to the Company, if at all. New Risk • Jul 10
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 11% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$6.4m free cash flow). Negative equity (-US$1.7m). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (US$24.7m market cap). Annonce • May 31
Zivo Bioscience, Inc. Announces its GRAS Designation Reaffirmed for Proprietary Algal Biomass Product as Human Food Ingredient Zivo Bioscience, Inc. announced it has received an updated dossier from an independent scientific review panel reconfirming the Company’s Generally Recognized As Safe (GRAS) designation for its proprietary algal biomass to be marketed and used as an ingredient in a defined range of foods and beverages for human consumption. GRAS is a designation created by the U.S. Food and Drug Administration (FDA) under the Federal Food, Drug and Cosmetic Act that determines if a food ingredient or additive has adequate evidence of safety to be consumed under the conditions of intended use. GRAS status conveys to manufacturers and marketers that they are able to safely integrate ZIVO’s algal biomass ingredient into food processing lines and products, and to include its nutritional information on product labels. The present GRAS review is based on commercial-scale cultivation processes and parameters, which better represent ZIVO’s planned commercial product. The analysis concludes that ZIVO’s algal biomass, as cultivated for commercial use, is exempt from the premarket approval requirements of the FDA. Annonce • May 29
Nasdaq Notifies Zivo Biosciences Regarding its Common Stock Delisting from Nasdaq Due to Non-Compliance with the Stockholders’ Equity Requirement On May 23, 2023, Zivo Biosciences, Inc. was notified by the Listing Qualifications department (the ‘Staff’) of The Nasdaq Stock Market LLC (‘Nasdaq’) that, based upon the Company’s non-compliance with the $2.5 million stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(b) (the ‘Rule’), as of May 22, 2023, the Company’s common stock was subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the ‘Panel’). The company plans to timely request a hearing before the Panel, which request will stay any further action by Nasdaq at least until the hearing process concludes and any extension that may be granted by the Panel has expired. At the hearing, the Company will present its plan to regain compliance with the Rule and request the continued listing its common stock pending the Company’s compliance with the Rule. There can be no assurances however that the Panel will grant the Company’s request or that the Company will be able to evidence compliance with all applicable Nasdaq listing criteria within any extension of time that may be granted by the Panel. As previously disclosed, the Staff granted the Company an extension to evidence compliance with the Rule through May 22, 2023. The Company was unable to do so, which resulted in the issuance of the Staff’s determination. Annonce • Feb 11
ZIVO Bioscience, Inc. Announces Results of Study with Its Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens ZIVO Bioscience, Inc. announced the results of a four-month study performed by a third party on behalf of a potential partner company, which included a 42-day coccidiosis trial in broiler chickens. The study evaluating the Company’s novel immune-modulating biologic for treating coccidiosis in broiler chickens produced questionable results due to a high disease burden among tested chickens. The pathogen inoculation used in the study produced an unexpectedly strong and concentrated disease challenge that resulted in a mortality rate 4-5 times higher than a typical study, and not representative of conditions expected in commercial broiler production houses. Despite efforts to titrate the inoculum in advance to assure an appropriate study environment, the disease burden was elevated far beyond naturally occurring or target study conditions. Based on numerous previously successful trials that more closely replicated disease levels observed in commercial production facilities, ZIVO remains confident that its novel product for broiler chickens represents a disruptive solution to coccidiosis, one of the most significant challenges facing the global poultry industry. Recent Insider Transactions • Dec 19
Independent Director recently bought US$72k worth of stock On the 13th of December, Alison Cornell bought around 24k shares on-market at roughly US$3.00 per share. This transaction increased Alison's direct individual holding by 8x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$506k more in shares than they have sold in the last 12 months. Recent Insider Transactions • Feb 17
Independent Director recently bought US$340k worth of stock On the 11th of February, Christopher Maggiore bought around 91k shares on-market at roughly US$3.72 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$383k more in shares than they have sold in the last 12 months. Executive Departure • Sep 23
Independent Director Robert Rondeau has left the company On the 17th of September, Robert Rondeau's tenure as Independent Director ended after 5.5 years in the role. As of June 2021, Robert still personally held only 1.56k shares (US$7.4k worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 2.67 years. Annonce • May 29
ZIVO Bioscience, Inc. has completed a Composite Units Offering in the amount of $13.8 million. ZIVO Bioscience, Inc. has completed a Composite Units Offering in the amount of $13.8 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 2,760,000
Price\Range: $5 Annonce • Apr 27
ZIVO Bioscience, Inc. Announces Us Patent Office Notice of Allowance for Administration of Proprietary Algal Biomass to Support Immune Health ZIVO Bioscience, Inc. announced the US Patent Office has issueda Notice of Allowance for the use of the company’s proprietary algal biomass product to promote a healthy immune response for use in dairy cattle. Follow-on patent filings for other animal species and humans are in process. This new patent allowance protects a nutritionally based approach that involves the administration of the Company’s proprietary algal culture in the form of extracts, supernatants and dried biomass to support and promote a robust and healthy immune response. However, the path of discovery, validation and optimization for bovine use began much earlier with aseries of in vitro experiments to determine the nutritional interactions and benefits exhibited by the algal culture generally. The cells and tissues used for these in vitro experiments were both human and animal because basic metabolic pathways are similar across species and the particular methods and models to conduct these in vitro experiments are well-documented and repeatable. Bovine applications were the first to be studied extensively and therefore the first of several patent applications filed for these particular health and nutrition benefits. With respect to immune health specifically, ZIVO scientists have observed lasting improvements in the immune health of young animals as well as in adults when its products are included in feed. The various in vitro and in vivo studies conducted over the years also support the use of the Company’s naturally derived products in nutraceuticals and functional foods for human consumption, as well. Prior research using mouse and dog in vitro, in vivo and ex vivo studies has shown the Company’s products may also be effective in addressing joint stiffness and documented that ZIVO nutritional products significantly outperformed glucosamine chondroitin, a leading ingredient in joint health supplements for humans and animals. Annonce • Feb 13
ZIVO Bioscience, Inc. Appoints Alison A. Cornell as Member of the Board On February 8, 2021, the board of directors of ZIVO Bioscience, Inc. (the Board" and the Company", respectively) appointed Ms. Alison A. Cornell to serve as a member of the Board and to fill a vacancy following the Board's resolution on the same date to increase its membership size from five (5) to six (6) members. Ms. Cornell currently serves as the Executive Vice President & Chief Financial Officer of Compassion-First Pet Hospitals, and has held such office since July 2017. Annonce • Jan 08
ZIVO Bioscience, Inc. Announces Executive Changes On January 1, 2021, the Board of Directors of ZIVO Bioscience, Inc. appointed Keith Marchiando as the Company's Chief Financial Officer effective immediately. Mr. Marchiando succeeds Philip Rice who stepped down from his role as Chief Financial Officer of the Company effective January 1, 2021, and who is remaining as a non-executive employee of the Company for a transition period. Mr. Marchiando, age 58, joins the Company from New US Nonwovens, LLC (Nonwovens"), a contract manufacturer of personal care and home care products, where he was Chief Financial Officer since August 2019. 